IPP Bureau
Enhertu Phase III results to redefine how metastatic breast cancer is classifed
By IPP Bureau - February 21, 2022
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
Snowman Logistics expands its facility in Coimbatore
By IPP Bureau - February 21, 2022
The facility will cater to the storage, handling and transportation of pharma, dairy products seafood among others
Sputnik Light gets a boost as China changes rules on boosters
By IPP Bureau - February 21, 2022
Sputnik Light can become a major booster for those vaccinated with inactivated Chinese Covid-19 vaccines globally after China has officially recommended mix & match approach with adenoviral vector-based vaccines as boosters
Gujarat unveils ambitious Biotech Policy 2022-27
By IPP Bureau - February 21, 2022
According to the state government, it will also provide support to special projects such as preclinical testing, genome sequencing in the private sector, private sector BSL-3 lab-vaccine development and manufacturing and testing and certification laboratories
Vestige launches Pre-Gluco Health capsules for the early prevention of diabetes
By IPP Bureau - February 21, 2022
According to the Indian Journal of Medical Research in 2018, the estimated prevalence of pre-diabetes in India is 14%, which means that one out of six Indians is pre-diabetic
Panacea Biotech partners with GOI to develop protective vaccine against betacoronavirus
By IPP Bureau - February 21, 2022
CEPI is accelerating its programme to develop broadly protective coronavirus vaccines—a core part of US $ 3.5 billion pandemic preparedness plan
VitaDAO and Molecule AG partner with Apollo Health Ventures to build the longevity biotech & Web3 ecosystem
By IPP Bureau - February 21, 2022
By connecting a leading LongBio VC to the DeSci (decentralized science) movement, this partnership is a major milestone for the greater decentralized ecosystem
Valneva receives funding for Covid-19 vaccine from Scotland
By IPP Bureau - February 21, 2022
The grants are expected to be received over the next three years, commencing March 2022
Corbevax receives EUA for 12-18 age group
By IPP Bureau - February 21, 2022
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
SEBI approves IPO plans of PharmEasy and Wellness Forever Medicare
By IPP Bureau - February 21, 2022
The companies plan to use the proceeds to retire debt and expand operations
Syncona completes sale of Gyroscope to Novartis
By IPP Bureau - February 20, 2022
The transaction generates upfront cash proceeds of $442 million for Syncona's holding in Gyroscope
Resolution Therapeutics strengthens its team with two new appointments
By IPP Bureau - February 20, 2022
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
GSK pauses phase III RSV maternal vaccine candidate programme
By IPP Bureau - February 20, 2022
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
Merck announces leadership team for human health business
By IPP Bureau - February 20, 2022
In the interim, Deepak Khanna will lead Human Health International.
USFDA lifts clinical hold on submission of Covaxin
By IPP Bureau - February 20, 2022
Covaxin is a whole-virion inactivated Covid-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades
